Abstract
This chapter is based on a shortened version of the investigators brochures from the EORTC clinical trials 11001 and 11011 concerning the boron compounds sodium borocaptate (BSH) and boronophenylalanine (BPA). It summarizes essential information that might be asked by regulatory authorities. The intention of this chapter is to support and to facilitate the preparation of new clinical trials based on these compounds. However, this compilation cannot offer a complete and final description of all aspects concerning these 2 compounds necessary to file for drug approval.
Cite
CITATION STYLE
Sauerwein, W. A. G., Bet, P. M., & Wittig, A. (2012). Drugs for BNCT: BSH and BPA. In Neutron Capture Therapy: Principles and Applications (Vol. 9783642313349, pp. 117–160). Springer-Verlag Berlin Heidelberg. https://doi.org/10.1007/978-3-642-31334-9_8
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
